Alerta

使用脂质纳米颗粒的核酸递送系统

Resumen de: KR20250036032A

The nucleic acid transfer complex is the helper lipid of 20 parts by weight to 5, the ionizable lipid of 40 parts by weight to 20, the cationic lipid of 30 parts by weight to 10, 0. Lipid nanoparticles including 5 to 3 parts by weight of polyethylene glycol lipid (lipid-anchored peg) and 30 to 50 parts by weight of cholesterol; and nucleic acids collected inside the lipid nanoparticles. The nucleic acid delivery complex of the present invention efficiently delivers nucleic acids to cells and gram-negative bacteria, thereby enabling the regulation and editing of gene expression.

一种改善精神障碍组合物及其制备方法

Resumen de: CN121775082A

本发明提出了一种改善精神障碍组合物及其制备方法，属于医药技术领域。将铁皮石斛、茯苓、大枣、五味子经过水提醇沉，得到水提中药多糖，滤液干燥得到水提取物，滤渣经过发酵，分别得到益生菌液、发酵中药多糖和发酵提取物，将发酵中药多糖包埋褪黑素、帕罗西汀后经过疏水改性，制得疏水改性包埋颗粒，将水提中药多糖羧基化，包埋益生菌得到益生菌包埋微球，与疏水改性包埋颗粒、水提取物和发酵提取物混合均匀，制得改善精神障碍组合物，具有很好的改善精神障碍、调节睡眠，改善抑郁等症状，也通过脑‑肠轴改善人的精神状态和情绪状况，中药滋阴调节人体状态，提高患者的依从性，提高药效的同时，降低了药物的成本。

索拉非尼协同四氧化三铁强化铁死亡的仿生纳米平台及其制备方法、应用

Resumen de: CN121774916A

本发明公开了一种索拉非尼协同四氧化三铁强化铁死亡的仿生纳米平台及其制备方法，所述仿生纳米平台包括SF/Fe3O4@PMO@MM纳米颗粒，所述SF/Fe3O4@PMO@MM纳米颗粒由内而外依次包括核心、壳层和膜层；其中，所述核心包括Fe3O4纳米颗粒；所述壳层包括包覆在所述核心表面的介孔有机硅层，所述介孔有机硅层与核心构成Fe3O4@PMO纳米颗粒，且所述介孔有机硅层的介孔内负载有索拉非尼（SF）；所述膜层包括包覆在所述壳层表面的巨噬细胞膜（MM）。本发明的纳米平台能够在肿瘤组织中通过级联反应高效生成活性氧（ROS）并协同索拉非尼诱导肿瘤细胞发生铁死亡，通过靶向肿瘤实现对肿瘤细胞的选择性杀伤，具有主动靶向、免疫逃逸、微环境响应及协同治疗功能。

靶向ACKR3的巨噬细胞膜纳米粒及其在脂肪肝IRI中的应用

Resumen de: CN121774915A

本发明公开了靶向ACKR3的巨噬细胞膜纳米粒及其在脂肪肝IRI中的应用，涉及生物医药和纳米技术领域；其制备方法包括：使用LPS预刺激巨噬细胞24h后使之发生极化并提取巨噬细胞膜，再使用巨噬细胞膜包被负载shACKR3的纳米颗粒得到LPS‑MM/PLGA‑shACKR3；以聚乳酸‑羟基乙酸共聚物PLGA作为纳米载体，负载具有特异性启动子的ACKR3‑shRNA质粒，制备得到纳米颗粒PLGA‑shACKR3；然后将LPS预刺激的巨噬细胞膜包被于PLGA‑shACKR3纳米颗粒表面，即得。本发明实现病变部位的主动靶向和高效蓄积。

一种环境响应型可注射复合水凝胶及其制备方法与应用

Resumen de: CN121774877A

一种环境响应型可注射复合水凝胶及其制备方法与应用，属于生物医用材料技术领域。为解决利用黄芪甲苷治疗动物骨关节炎（OA）生物利用度低及可注射水凝胶在治疗OA时功能单一、载药与释药效率有待提升等技术问题，本发明利用物理‑化学双交联原理，使改性的HA和COS发生席夫碱化学反应，形成第一网络结构；使改性HA、SA、COS与PDA生成多种物理交联反应，形成第二网络结构；以关节腔中钙离子作为引发剂，与SA发生离子交联，形成环境触发的水凝胶第三网络结构，从而构建得到具有多重网络结构的复合水凝胶。本发明制备的可注射复合水凝胶对OA表现出显著治疗效果，对于推进OA的临床治疗具有重大的理论意义和实际应用价值。

一种牛血清白蛋白包普鲁士蓝载药纳米粒及其制备方法和用途

Resumen de: CN121774910A

本发明涉及药物制剂技术领域，具体公开了一种牛血清白蛋白包普鲁士蓝载药纳米粒及其制备方法和用途，所述载药纳米粒为牛血清白蛋白包普鲁士蓝载药纳米粒，是将姜黄素(Curcumin，Cur)通过疏水作用共载到普鲁士蓝表面获得。本发明提供的载药纳米粒能显著提高药物在动脉粥样硬化微环境中积累和保留时间。静脉注射给药后可以实现被动靶向，在炎症部位释放出普鲁士蓝和姜黄素，普鲁士蓝凭借本身的类酶活性清除炎症部位的活性氧，并且辅以808纳米激光照射，普鲁士蓝发挥光热效应增加泡沫细胞内脂质的外排，联合姜黄素的抗炎特性，提高治疗效果。

一种负载卡巴他赛的pH/ROS双响应性纳米材料及其制备方法与应用

Resumen de: CN121774917A

本发明涉及新型纳米材料技术领域，公开了一种负载卡巴他赛的pH/ROS双响应性纳米材料及其制备方法与应用，该纳米材料以pH/ROS双响应材料为载体，载体上负载有卡巴他赛，pH/ROS双响应材料由环糊精与肉桂醛主要成分CA、HPAP偶联合成。本发明体外和体内实验表明，CBZ/FA‑CA‑OCD NPs能够富集于肿瘤组织，并通过FA介导的内吞作用被PC‑3和LNCaP细胞摄取。这些富集的纳米颗粒在酸性微环境和/或高活性氧微环境中可迅速释放卡巴他赛，进而有效抑制前列腺癌的生长。将CBZ/FA‑CA‑OCD NPs与抗PD‑1抗体联合使用，可显著增加CD8+和CD4+T细胞的浸润，逆转前列腺癌的免疫抑制微环境，并明显抑制肿瘤生长。本发明为调控肠道菌群以提高前列腺癌化疗免疫联合疗法的有效性提供了一种极具前景的策略。

一种提升姜黄素和胡椒碱稳定性和生物利用度的复合颗粒及其制备方法

Resumen de: CN121774912A

本发明提供了一种提升姜黄素和胡椒碱稳定性和生物利用度的复合颗粒及其制备方法，属于营养活性成分递送体系技术领域。本发明以卡拉胶、胡椒碱和壳聚糖为原料，使用反溶剂共沉淀法和逐层组装技术，将姜黄素和胡椒碱共载于姜黄素‑玉米醇溶蛋白‑卡拉胶‑胡椒碱‑壳聚糖复合颗粒中。与游离姜黄素和胡椒碱相比，本发明构建的层层结构复合颗粒作为姜黄素和胡椒碱的共包埋递送载体，不仅可以增加姜黄素和胡椒碱的理化稳定性，还显著提高了姜黄素和胡椒碱的生物活性和效能，显著延长了姜黄素和胡椒碱的体内滞留时间，提高生物利用度。

一种RNA及含有RNA的药物

Resumen de: CN121780566A

本申请公开了一种RNA及含有RNA的药物，所述RNA包含开放阅读框(ORF)，所述开放阅读框(ORF)编码O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA。本申请还提供一种含有药物组合物、蛋白、DNA分子、重组质粒、RNA药物及其用途。在本申请提供的RNA，通过载体进行递送，所述RNA在体内利用自身的原料和翻译机制合成O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA，从而实现O‑GlcNAc糖基转移酶OGT或O‑GlcNAc糖苷水解酶OGA对体内靶蛋白糖的修饰作用。

mRNA-LNP制剂及其冻干方法

Resumen de: CN121782826A

本发明公开了一种mRNA‑LNP制剂及其冻干方法，冻干方法包括如下步骤：取mRNA‑LNP纳米颗粒和冻干保护剂组合物混合，得到混合物：将混合物先进行预冻，得到冻结体；在低于冻结体共晶点温度的条件下，将冻结体进行升华干燥，得到初产物；将初产物进行解析干燥，得到mRNA‑LNP制剂。本发明采用超低温预冻、缓慢解析干燥、低温终点冻干曲线制备出稳定的纳米粒径、相当高的核酸包封率及其生物活性的mRNA‑LNP样品，该mRNA‑LNP样品可在常温下长时间保存。

腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌

Resumen de: WO2024246004A1

The present invention relates to a diagnostic method (100) for diagnosing a state of a cell stack (300) of an electrochemical energy converter. The diagnostic method (100) comprises: - connecting (101) a plurality of bipolar plates (301) of the cell stack (300) to a cell voltage measurement system (311), - ascertaining (103) measurement values for each cell (303) of the plurality of cells (303) by means of the cell voltage measurement system (311), - determining (105) a characteristic value for each cell (303) of the plurality of cells (303) on the basis of measurement values ascertained by means of the cell voltage measurement system (311), - comparing (107) the characteristic value with a specified quality criterion, - outputting (109) an error message if the characteristic value does not satisfy the quality criterion, wherein the ascertaining of measurement values is carried out in a dry state of the cell stack (300).

NR1D1抑制剂在制备用于治疗脓毒症的药物中的用途

Resumen de: CN121775000A

本发明属于生物医药领域，涉及NR1D1抑制剂在制备用于治疗脓毒症的药物中的用途，该NR1D1抑制剂包含能特异性靶向沉默NR1D1基因的siRNA，能够上调BMAL1并恢复IGF2BP2‑ ATP6V1B2/ATP6V0c轴，显著改善脓毒症免疫抑制及继发感染防御。

IMPROVED NANOSEEDING PROCESS

Resumen de: WO2026068294A1

What is described herein relates to a method for generating micro-particles comprising the steps of providing an aqueous nanosuspension comprising nanoparticles as seeding material characterized by a nano-particle size in at least one of length, diameter or height of a d90 in the range of 10 nm and 999 nm as measured by Dynamic Light Scattering (DLS), laser diffraction or electron microscopy and at least one stabilizer, providing a homogenous saturated solution of a substance in a crystallization medium where said substance is the same substance as the substance constituting the nanoparticles in the nanosuspension mixing the homogenous saturated solution and the aqueous nanosuspension comprising nanoparticles as seeding material at a supersaturation level with respect to the substance in the range of 1 and 1000 optionally isolating micro-particles.

Shared antigens

Resumen de: AU2026200326A1

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines. an a n

METHODS OF USING POLYMER NANOPARTICLE COMPOSITIONS FOR TREATING A DISEASE

Resumen de: US20260090998A1

The disclosure relates to methods of using block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to methods of using polymer nanoparticles for delivering nucleic acids for treating NF1.

NANOPARTICLE THERAPEUTIC VACCINES THAT SIMULTANEOUSLY CO-DELIVER MHC CLASS I AND MHC CLASS II ANTIGENS AND AN ADJUVANT

Resumen de: WO2026073053A1

Provided is a nanoparticle vaccine delivery7 platform that simultaneously co-delivers MHC class I and II restricted antigens and an adjuvant. Also provided is the use of the nanoparticle vaccine delivery platform to is elicit a targeted immune response in a subject having or suspected of having or suspected of having cancer, an autoimmune disease, or an autoimmune state. Additionally provided are methods for immunizing a subject having or suspected of having a cancer, an autoimmune disease, or an autoimmune state with the nanoparticle vaccine delivery platform.

COMPOSITIONS AND USE OF DRY POWDER LIPID NANOPARTICLES

Resumen de: WO2026068222A1

Provided herein are embodiments of composition that include one or more particulates. Several embodiments provide one or more particulates that include one or more lipid nanoparticles coated in an excipient matrix, and encapsulating at least one pharmaceutically active ingredient. Several embodiments provide for particulates that at least partially encapsulate the pharmaceutically active ingredient and the excipient matrix that at least partially cover the outside of the particulates.

NANO-INJECTION, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026067225A1

Provided are a nano-injection, and a preparation method therefor and a use thereof. The nano-injection has good stability, a controllable particle size, and a narrow particle size distribution range; and the nano-injection can be used for intravenous injection, acts rapidly, can effectively control drug burst release during injection, ensures steady drug release, provides a long duration of action, exhibits an excellent analgesic effect, and offers good safety.

HIGH DENSITY BRUSH SHAPED POLYMER LIPIDS REDUCE ANTI-PEG ANTIBODY BINDING TO ENABLE MRNA LIPID NANOPARTICLE REPEAT ADMINISTRATION

Resumen de: WO2026073266A1

The present disclosure relates to a compound containing two or more hydrophobic chains and a polyacrylate polymer with one or more PEG side chains attached to the carboxylic acid group of the polyacrylate polymer. The compound is further defined by formula I: wherein the variables are as defined below. These compounds may be used in the preparation of lipid nanoparticles for the treatment or prevention of a disease or disorder.

SIROLIMUS-ALBUMIN COMPOSITION AND PREPARATION METHOD THEREFOR

Resumen de: WO2026067584A1

The present application discloses a sirolimus-albumin composition and a preparation method therefor. The preparation method of the present application incorporates an incubation step before solvent removal via evaporation of liquid having undergone high-pressure homogenization, thereby resulting in more uniform nanoparticles and further improving the physical stability of a nanosuspension and the chemical stability of a formulation without the need for any stabilizer. Compared with marketed products, the sirolimus-albumin composition of the present application can be completely dissolved within 1-3 min, the reconstitution operation is simpler, and a nanoparticle suspension after reconstitution remains stable at 30°C for 24 h, thereby offering greater convenience for clinical use. In addition, the composition of the present application can be stored at room temperature, is convenient to transport, and has a longer shelf life.

JANUS PARTICLE-EMBEDDED MATERIALS FOR ANTIMICROBIAL APPLICATIONS

Resumen de: US20260091127A1

Antimicrobial Janus nanoparticles (NPs) having distinct hydrophobic and polycationic surfaces are embedded in crosslinked polymers. These encapsulated Janus NPs have increased stabilization, to allow for long-term effectiveness. The encapsulated Janus NPs enhance traditional antibiotics and reduce the necessary dosage of those traditional antibiotics to inhibit growth of muti-drug resistant bacteria.

Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery

Resumen de: US20260092134A1

Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.

LIPID NANOPARTICLE FORMULATIONS OF TREMS

Resumen de: WO2026073261A1

The disclosure relates generally to tRNA-based effector molecules (TREMs) formulated in lipid nanoparticles having a non-naturally occurring modification and compositions and methods relating thereto.

LIPID-BASED NANOPARTICLES COMPRISING NON-GLYCOSYLATED FC DOMAINS AND USES THEREOF

Resumen de: WO2026068705A1

The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain covalently linked to a nonglycolsylated Fc domain, and uses thereof.

COMPOUND HAVING DISULFIDE BOND AND METHOD FOR PRODUCING SAME

Nº publicación: WO2026070952A1 02/04/2026

Solicitante:

NOF CORP [JP]
\u65E5\u6CB9\u682A\u5F0F\u4F1A\u793E

Resumen de: WO2026070952A1

The present invention provides a method for producing a compound (1), the method comprising the following step 1a:　step 1a for reacting a compound (3) and a compound (4) in a two-phase system containing an organic base, an inorganic base, water, and a water-insoluble organic solvent, thereby obtaining the compound (1). The definitions of the symbols in the formula are as described in the description.